These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35666038)

  • 1. Radiotherapy with continued EGFR-TKIs for oligoprogressive disease in EGFR-mutated non-small cell lung cancer: A real-world study.
    Hu C; Wu S; Deng R; Wu Y; Pan Y; Shu L; Wu F
    Cancer Med; 2023 Jan; 12(1):266-273. PubMed ID: 35666038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
    Qiu B; Liang Y; Li Q; Liu G; Wang F; Chen Z; Liu M; Zhao M; Liu H
    Clin Lung Cancer; 2017 Nov; 18(6):e369-e373. PubMed ID: 28465010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local Thermal Ablation with Continuous EGFR Tyrosine Kinase Inhibitors for EGFR-Mutant Non-small Cell Lung Cancers that Developed Extra-Central Nervous System (CNS) Oligoprogressive Disease.
    Ni Y; Liu B; Ye X; Fan W; Bi J; Yang X; Huang G; Li W; Wang J; Han X; Wei Z; Meng M
    Cardiovasc Intervent Radiol; 2019 May; 42(5):693-699. PubMed ID: 30701290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases.
    Yu X; Sheng J; Pan G; Fan Y
    Int J Cancer; 2021 Sep; 149(5):1121-1128. PubMed ID: 33970485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local ablative radiotherapy on oligo-progression while continued on epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer patients: A longer cohort.
    Mok FST; Tong M; Loong HH; Mok TSK
    Asia Pac J Clin Oncol; 2022 Dec; 18(6):614-624. PubMed ID: 35098663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic body radiotherapy to the primary lung lesion improves the survival of the selected patients with non-oligometastatic NSCLC harboring EGFR activating mutation with first-line EGFR-TKIs: a real-world study.
    Wei H; Zhou X; Yang H; Gong Y; Wang J; Xu Y; Zhou L; Xue J; Zou B; Zhang Y; Zhu J; Peng F; Huang M; Lu Y; Liu Y
    J Cancer Res Clin Oncol; 2022 Oct; 148(10):2589-2598. PubMed ID: 34669037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of EGFR-TKIs on survival in advanced non-small-cell lung cancer with EGFR mutations: A real-world study.
    Yu X; Si J; Wei J; Wang Y; Sun Y; Jin J; Zhang X; Ma T; Song Z
    Cancer Med; 2023 Mar; 12(5):5630-5638. PubMed ID: 36380563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the Efficacy of EGFR-TKIs Combined With Radiotherapy in Advanced Lung Adenocarcinoma Patients With EGFR Mutation: A Retrospective Study.
    Wang Y; Yu W; Shi J; Qiu R; Jiang N; Wang Z; Yang J; Jia Z; Song M
    Technol Cancer Res Treat; 2022; 21():15330338221100358. PubMed ID: 35607295
    [No Abstract]   [Full Text] [Related]  

  • 9. EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases.
    Jiang T; Chu Q; Wang H; Zhou F; Gao G; Chen X; Li X; Zhao C; Xu Q; Li W; Wu F; Xiong A; Zhao J; Xu Y; Su C; Ren S; Zhou C; Hirsch FR
    Int J Cancer; 2019 May; 144(10):2605-2612. PubMed ID: 30387880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Local microwave ablation with continued EGFR tyrosine kinase inhibitor as a treatment strategy in advanced non-small cell lung cancers that developed extra-central nervous system oligoprogressive disease during EGFR tyrosine kinase inhibitor treatment: A pilot study.
    Ni Y; Bi J; Ye X; Fan W; Yu G; Yang X; Huang G; Li W; Wang J; Han X; Ni X; Wei Z; Han M; Zheng A; Meng M; Xue G; Zhang L; Wan C
    Medicine (Baltimore); 2016 Jun; 95(25):e3998. PubMed ID: 27336903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Radiotherapy in Epidermal Growth Factor Receptor Mutation-positive Patients with Oligoprogression: A Matched-cohort Analysis.
    Chan OSH; Lee VHF; Mok TSK; Mo F; Chang ATY; Yeung RMW
    Clin Oncol (R Coll Radiol); 2017 Sep; 29(9):568-575. PubMed ID: 28499791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential treatment in advanced non-small cell lung cancer harboring EGFR mutations.
    Hsu PC; Chang JW; Chang CF; Huang CY; Yang CT; Kuo CS; Fang YF; Wu CE
    Ther Adv Respir Dis; 2022; 16():17534666221132731. PubMed ID: 36305280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of re-challenging 160 mg furmonertinib for advanced NSCLC after resistance to third-generation EGFR-TKIs targeted agents: A real-world study.
    Qi R; Fu X; Yu Y; Xu H; Shen M; He S; Lv D
    Lung Cancer; 2023 Oct; 184():107346. PubMed ID: 37604026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial.
    Lim SW; Park S; Kim Y; Cho JH; Park SE; Lee H; Kim HK; Kim SM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Lung Cancer; 2018 Oct; 124():293-297. PubMed ID: 30268476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment: A cohort study.
    Yu Y; Wang Y; Wu L; Xu X; Zhou H; Wang Q; Zhou J
    Medicine (Baltimore); 2021 Feb; 100(5):e23712. PubMed ID: 33592829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M.
    Huang YH; Tseng JS; Hsu KH; Chen KC; Su KY; Yu SL; Chen JJW; Yang TY; Chang GC
    Sci Rep; 2021 Jun; 11(1):12084. PubMed ID: 34103652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Survival analysis of different kinds of tyrosine kinase inhibitors in the treatment of patients with epidermal growth factor receptor mutated non-small cell lung cancer and leptomeningeal metastasis].
    Xu HY; Chen HQ; Kong JX; Zhang Y; Liu S; Yang GJ; Wang Y
    Zhonghua Yi Xue Za Zhi; 2022 Feb; 102(6):399-405. PubMed ID: 35144338
    [No Abstract]   [Full Text] [Related]  

  • 18. Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.
    Chen Q; Quan Q; Ding L; Hong X; Zhou N; Liang Y; Wu H
    Oncotarget; 2015 Sep; 6(28):24904-11. PubMed ID: 26172562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
    Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
    Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of surgery and subsequent therapy for central nervous system oligoprogression in EGFR-mutated NSCLC patients.
    Perng PS; Hsu HJ; Lee JS; Wang LC; Huang CY; Tien CH; Lai YH; Su PL; Hsu HH; Chen LY; Lee PH
    World J Surg Oncol; 2023 Nov; 21(1):368. PubMed ID: 38007448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.